Cargando…

PB2324: SAFE ADMINISTRATION OF SECOND DOSE OF MRNA COVID-19 VACCINE FOLLOWING DEVELOPMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA

Detalles Bibliográficos
Autores principales:	Hajizadeh Barfejani, A., Prasad, S., Henry, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431490/ http://dx.doi.org/10.1097/01.HS9.0000852120.42895.8a

Ejemplares similares

PB2658: IMMUNE THROMBOCYTOPENIC PURPURA IN ALBANIA
por: Grazhdani, Sara, et al.
Publicado: (2023)

PB2309: EVALUATION OF MORBIMORTALITY FACTORS OF PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Pinto, M. I., et al.
Publicado: (2022)

PB2304: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP): A SINGLE-CENTER EXPERIENCE
por: Kammoun, F., et al.
Publicado: (2022)

PB2634: USE OF N-ACETYLCYSTEINE THERAPY IN PATIENTS WITH RELAPSED REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Beyler, Ozlem, et al.
Publicado: (2023)

PB1889: A CASE OF REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INDUCED IMMUNE THROMBOCYTOPENIC PURPURA SUCCESSFULLY TREATED WITH VENETOCLAX
por: Yavuz, B., et al.
Publicado: (2022)

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.
por: Martinez, Celia, et al.
Publicado: (2023)

PB2261: LINEZOLID AS A SAFE ANTIMICROBIAL AGENT IN THROMBOCYTOPENIC PATIENTS UNDERGOING CHEMOTHERAPY FOR HEMATOLOGIC MALIGNANCIES
por: Angotzi, F., et al.
Publicado: (2022)

PB2627: THROMBOTIC THROMBOCYTOPENIC PURPURA, RELAPSE RELATED RISK FACTORS IN A CARE CENTER WITH LIMITED ACCESS TO ADAMTS13 LEVELS.
por: Goya, Santiago Riviello, et al.
Publicado: (2023)

COVID-19 Vaccination Associated Severe Immune Thrombocytopenic Purpura
por: Sharawi, Said, et al.
Publicado: (2022)

Idiopathic thrombocytopenic purpura
por: Kayal, L., et al.
Publicado: (2014)

A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura
por: Goreshnik, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

mRNA-1273: Idiopathic thrombocytopenic purpura: case report
Publicado: (2021)

mRNA-1273: Idiopathic thrombocytopenic purpura: case report
Publicado: (2021)

PB2188: PROTON PUMP INHIBITORS ARE SAFE AND EFFECTIVE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA TREATED WITH LOW-DOSE ASPIRIN
por: Krecak, Ivan, et al.
Publicado: (2023)

Octaploidy in idiopathic thrombocytopenic purpura
por: Makroo, R. N., et al.
Publicado: (2011)

PB1796: ADMINISTRATION OF A KETOGENIC DIET FOR CHEMOTHERAPY PROTECTION IN ACUTE LEUKEMIA PATIENTS: IS IT FEASIBLE, SAFE, AND VALUABLE? PRELIMINARY RESULTS OF THE RANDOMIZED CONTROLLED TRIAL LEU-KETO STUDY.
por: Cagigas, Maria Lastra, et al.
Publicado: (2023)

PB2392: MRNA IDENTIFICATION OF TIGIT IN PERITUMORAL LYMPHOCYTES IN CLASSICAL HODGKIN DISEASE
por: Annibali, Ombretta, et al.
Publicado: (2023)

PB1883: IMPLANTATION AND LONG-TERM USE OF PERIPHERALLY-INSERTED CENTRAL CATHETER ARE SAFE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKAEMIA
por: Szotkowski, Tomáš, et al.
Publicado: (2023)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

PB2176: MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS
por: Stolyar, Marina, et al.
Publicado: (2023)

PB2326: SAFE AND EFFECTIVE PROPHYLAXIS WITH PLASMA-DERIVED FACTOR X CONCENTRATE IN AN ELDERLY PATIENT WITH HEREDITARY FACTOR X DEFICIENCY
por: Patel, H., et al.
Publicado: (2022)

PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
por: Catania, Federica, et al.
Publicado: (2023)

PB2605: EFFICACY AND SAFETY OF MRNA COVID VACCINES IN ITP PATIENTS: A MONOCENTRIC REAL-LIFE STUDY
por: D’angelo, Simona, et al.
Publicado: (2023)

Immune Thrombocytopenia Purpura Relapse in Patients Who Received mRNA COVID-19 Vaccines
por: Qasim, Hana, et al.
Publicado: (2022)

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, L., et al.
Publicado: (2022)

Borderline Thrombocytopenia or Mild Idiopathic Thrombocytopenic Purpura?
por: Zimmer, Jacques, et al.
Publicado: (2006)

Successful treatment with erythromycin for idiopathic thrombocytopenic purpura
por: Ohe, Masashi, et al.
Publicado: (2011)

Idiopathic thrombocytopenic purpura coexisting with polycythemia vera
por: Niscola, Pasquale, et al.
Publicado: (2011)

Idiopathic thrombocytopenic purpura in women with breast cancer
por: Samimi, Mozhgan Alam, et al.
Publicado: (2010)

Pregnancy outcomes in women with idiopathic thrombocytopenic purpura
por: Yassaee, Fakhrolmolouk, et al.
Publicado: (2012)

Idiopathic Thrombocytopenic Purpura Masquerading Paediatric SLE
por: Barara, Meenu, et al.
Publicado: (2015)

Idiopathic Thrombocytopenic Purpura Misdiagnosed as Hereditary Angioedema
por: Andersen, Michelle Fog, et al.
Publicado: (2015)

Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura
por: Akyol Erikçi, Alev, et al.
Publicado: (2016)

Idiopathic Thrombocytopenic Purpura Related to COVID-19
por: Langhi, Mariana M., et al.
Publicado: (2020)

Tozinameran: Idiopathic thrombocytopenic purpura: case report
Publicado: (2021)

PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE
por: Borst, Carla, et al.
Publicado: (2023)

Dengue Infection Triggering Concurrent Thrombotic Thrombocytopenic Purpura in a Case of Chronic Idiopathic Thrombocytopenic Purpura
por: Rana, Akash, et al.
Publicado: (2023)

PB1789: WT1, HMGA2, EVI1, BAALC AND PRAME MRNA LEVELS IN PATIENTS BLOOD SAMPLES WITH ACUTE LEUKEMIA
por: Stolyar, M., et al.
Publicado: (2022)

PB2236: HUMORAL RESPONSE TO SARS-COV-2 VACCINATION WITH BNT162B2 COVID-19 MRNA IN PATIENTS WITH HAEMOGLOBINOPATHIES
por: Giatagantzidou, I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9flrc2k3vl3luv7g2n00um9iue